{
    "nctId": "NCT06299202",
    "briefTitle": "Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy",
    "officialTitle": "Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "The evolution of the relative tumor enhancement (RTEe) (%) between the baseline and early re-evaluation CESM",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* With a histological diagnosis of stage II or III localised breast cancer, with an indication for first or neoadjuvant chemotherapy validated by the RCP: HER2+, Triple negative\n* Affiliated or beneficiary of a social security scheme or similar\n* Having signed an informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patients considered to be at very high risk (BRCA 1 and 2 mutation, Li Fraumeni syndrome, Lynch syndrome, previous thoracic irradiation for lymphoma) and high genetic risk as determined by an oncogenetic consultation\n* Pregnancy, breastfeeding\n* Contraindication to the injection of iodinated contrast material: hypersensitivity to the active substance or to one of the excipients of the contrast material, renal insufficiency with glomerular filtration rate \\< 35ml/min\n* Patients who do not master the French language\n* Patient who is an adult protected by law, under curatorship or guardianship\n* Patient who has participated in another research study with a current exclusion period",
    "sex": "FEMALE",
    "minimumAge": "35 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}